Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 01:40 am
Share
Medy-Tox Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported negative sales was KRW 0.00022 million compared to KRW 0.00046 million a year ago. Net income was KRW 13,208.03 million compared to KRW 20,624.75 million a year ago. Basic earnings per share from continuing operations was KRW 2,098.0952 compared to KRW 3,226.3038 a year ago. Diluted earnings per share from continuing operations was KRW 2,102.8571 compared to KRW 3,431.4286 a year ago. Basic earnings per share was KRW 2,098.0952 compared to KRW 3,387.619 a year ago. Diluted earnings per share was KRW 2,102.8571 compared to KRW 3,431.4286 a year ago.
For the nine months, negative sales was KRW 0.00026 million compared to KRW 0.0003 million a year ago. Net income was KRW 37,491.73 million compared to KRW 107,455.27 million a year ago. Basic earnings per share from continuing operations was KRW 5,785.7143 compared to KRW 16,806.3492 a year ago. Diluted earnings per share from continuing operations was KRW 5,761.9048 compared to KRW 16,745.5781 a year ago. Basic earnings per share was KRW 5,785.7143 compared to KRW 17,646.6667 a year ago. Diluted earnings per share was KRW 5,761.9048 compared to KRW 17,582.8571 a year ago.
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Companyâs main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
MEDY-TOX INC. 
